{
  "ticker": "VYGR",
  "company_name": "Voyager Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03065192",
      "title": "Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease, Brain Diseases, Central Nervous System Diseases, Movement Disorders, Nervous System Diseases, Neurodegenerative Diseases, Parkinsonian Disorders",
      "start_date": "2017-05-11",
      "completion_date": "2021-08-10",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    },
    {
      "nct_id": "NCT03562494",
      "title": "VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Parkinson's Disease",
      "start_date": "2018-10-17",
      "completion_date": "2024-10-30",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    },
    {
      "nct_id": "NCT06874621",
      "title": "VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Alzheimer&#39;s Disease (AD)",
      "start_date": "2025-03-03",
      "completion_date": "2027-05",
      "enrollment": 0,
      "sponsor": "Voyager Therapeutics"
    },
    {
      "nct_id": "NCT03733496",
      "title": "Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Parkinson's Disease",
      "start_date": "2018-08-24",
      "completion_date": "2023-07-18",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    },
    {
      "nct_id": "NCT04885114",
      "title": "Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease",
      "status": "WITHDRAWN",
      "phase": "PHASE1",
      "condition": "Huntington Disease",
      "start_date": "2021-07-30",
      "completion_date": "2024-12-30",
      "enrollment": 0,
      "sponsor": "Voyager Therapeutics"
    },
    {
      "nct_id": "NCT01973543",
      "title": "Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Parkinson's Disease",
      "start_date": "2013-10",
      "completion_date": "2020-01-24",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    }
  ],
  "summary": {
    "total_trials": 6,
    "by_phase": {
      "PHASE1": 4,
      "PHASE1, PHASE2": 1,
      "": 1
    },
    "by_status": {
      "COMPLETED": 4,
      "ACTIVE_NOT_RECRUITING": 1,
      "WITHDRAWN": 1
    },
    "active_trials": 1,
    "completed_trials": 4,
    "conditions": [
      "Alzheimer&#39;s Disease (AD)",
      "Huntington Disease",
      "Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease, Brain Diseases, Central Nervous System Diseases, Movement Disorders, Nervous System Diseases, Neurodegenerative Diseases, Parkinsonian Disorders",
      "Parkinson's Disease"
    ],
    "lead_stage": "phase_1"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:22:55.411421",
    "search_query": "Voyager Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Voyager+Therapeutics,+Inc."
  }
}